Format

Send to

Choose Destination
Adv Exp Med Biol. 2018;1075:3-30. doi: 10.1007/978-981-13-0484-2_1.

HIV Vaccine Efficacy Trials: RV144 and Beyond.

Heger E1, Schuetz A2,3,4, Vasan S5,6,7.

Author information

1
US Army Medical Materiel Development Activity, Fort Detrick, MD, USA.
2
US Army Medical Component, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand.
3
US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
4
Henry M. Jackson Foundation, Bethesda, MD, USA.
5
US Army Medical Component, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand. vasans@hiv-th.org.
6
US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA. vasans@hiv-th.org.
7
Henry M. Jackson Foundation, Bethesda, MD, USA. vasans@hiv-th.org.

Abstract

Despite progress in antiretroviral therapy, pre-exposure prophylaxis, microbicides, and other preventive strategies, a vaccine to prevent HIV-1 infection remains desperately needed. Development of an effective vaccine is challenged by several immunologic features of HIV-1 evidenced by the failure of five of the six HIV-1 candidate vaccine efficacy trials to date. This chapter reviews these efficacy trials with a focus on the Phase 3 RV144 trial in Thailand, the only HIV-1 vaccine efficacy trial to show a moderate protective effect of 31% with respect to placebo administration. Although modest, this protection has allowed for the study of potential immunologic correlates of protection to improve development of future HIV-1 pox-protein and other vaccine strategies. Trials in Thailand and South Africa have built upon the RV144 framework to provide additional immunologic insights which enable current and future efficacy testing of related vaccine candidates.

KEYWORDS:

Correlates; Efficacy; HIV; Immunogenicity; Vaccine

PMID:
30030787
DOI:
10.1007/978-981-13-0484-2_1
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center